<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03433911</url>
  </required_header>
  <id_info>
    <org_study_id>CP-100-007</org_study_id>
    <nct_id>NCT03433911</nct_id>
  </id_info>
  <brief_title>FemBlocÂ® Contraception Pivotal Trial</brief_title>
  <acronym>BLOC</acronym>
  <official_title>BLOC: Prospective Multi-Center Office Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Femasys Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Femasys Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multi-center, international, non-randomized, two-arm study of subjects
      undergoing either FemBloc or laparoscopic bilateral tubal sterilization (Control). The
      FemBloc group total study duration will be approximately 65 months. The laparoscopic tubal
      sterilization (Control) group total study duration will be approximately 62 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed pregnancy rate for subjects told to rely on FemBloc for birth control</measure>
    <time_frame>1 year from being told to rely</time_frame>
    <description>Confirmed pregnancy rate for subjects told to rely on FemBloc for birth control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reliance rate</measure>
    <time_frame>Within 1 year</time_frame>
    <description>Number of subjects told to rely divided by number of qualified subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term pregnancy rate for subjects told to rely on FemBloc for birth control</measure>
    <time_frame>2-5 years</time_frame>
    <description>Long-term pregnancy rate for subjects told to rely on FemBloc for birth control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of short-term and long-term adverse events in each arm</measure>
    <time_frame>1-5 years</time_frame>
    <description>Safety: Incidence of short-term and long-term adverse events in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction/comfort assessed by questionnaire</measure>
    <time_frame>1-5 years</time_frame>
    <description>Satisfaction/comfort assessed by subject questionnaire at various timepoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">975</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>FemBloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational device and procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Laparoscopic bilateral tubal sterilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FemBloc</intervention_name>
    <description>Treatment with FemBloc for women who desire permanent birth control (female sterilization)</description>
    <arm_group_label>FemBloc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic bilateral tubal sterilization</intervention_name>
    <description>Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 21 - 45 years of age desiring permanent birth control

          -  Sexually active with male partner

          -  For FemBloc Arm:

               -  Regular menstrual cycle for last 3 months or on hormonal contraceptives

          -  For Control Arm:

               -  Undergoing planned laparoscopic bilateral tubal sterilization

        Exclusion Criteria:

          -  Uncertainty about the desire to end fertility

          -  Known or suspected pregnancy

          -  Prior tubal surgery, including sterilization attempt

          -  Prior endometrial ablation

          -  Presence, suspicion, or previous history of gynecologic malignancy

          -  Abnormal uterine bleeding requiring evaluation or treatment

          -  Scheduled to undergo concomitant intrauterine procedures at the time of procedure(s)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sponsor</last_name>
    <role>Study Director</role>
    <affiliation>Medical Affairs &amp; Clinical Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visions Clinical Research - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research Inc.</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virtus Research Consultants, LLC</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosemark Womencare Specialists</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Advantage</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers, The State University of New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amy Brenner MD &amp; Associates</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research LLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fembloc.com/</url>
    <description>FemBloc Study Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>February 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2018</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Permanent contraception</keyword>
  <keyword>Birth control</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

